How to buy Corbus Pharmaceuticals stock

Corbus Pharmaceuticals Holdings, Inc is a biotechnology business based in the US. Corbus Pharmaceuticals shares (CRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Corbus Pharmaceuticals employs 76 staff and has a trailing 12-month revenue of around 0.00.

Corbus Pharmaceuticals share price

Use our graph to track the performance of CRBP stocks over time.

Corbus Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-05-08.

52-week range	$0.91 - $9.78
50-day moving average	$1.86
200-day moving average	$1.76
Wall St. target price	$2.23
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.93

Buy Corbus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Corbus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Corbus Pharmaceuticals Holdings, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corbus Pharmaceuticals financials

Revenue TTM	$3.9 million
Gross profit TTM	$-94,329,983
Return on assets TTM	-101.37%
Return on equity TTM	-432.68%
Profit margin	0%
Book value	$0.46
Market capitalisation	$206.3 million

TTM: trailing 12 months

Shorting Corbus Pharmaceuticals shares

There are currently 13.4 million Corbus Pharmaceuticals shares held short by investors – that's known as Corbus Pharmaceuticals's "short interest". This figure is 23.9% up from 10.8 million last month.

There are a few different ways that this level of interest in shorting Corbus Pharmaceuticals shares can be evaluated.

Corbus Pharmaceuticals's "short interest ratio" (SIR)

Corbus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corbus Pharmaceuticals shares currently shorted divided by the average quantity of Corbus Pharmaceuticals shares traded daily (recently around 4.2 million). Corbus Pharmaceuticals's SIR currently stands at 3.2. In other words for every 100,000 Corbus Pharmaceuticals shares traded daily on the market, roughly 3200 shares are currently held short.

However Corbus Pharmaceuticals's short interest can also be evaluated against the total number of Corbus Pharmaceuticals shares, or, against the total number of tradable Corbus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corbus Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Corbus Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1081% of the tradable shares (for every 100,000 tradable Corbus Pharmaceuticals shares, roughly 108 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Corbus Pharmaceuticals.

Find out more about how you can short Corbus Pharmaceuticals stock.

Corbus Pharmaceuticals share dividends

We're not expecting Corbus Pharmaceuticals to pay a dividend over the next 12 months.

Corbus Pharmaceuticals share price volatility

Over the last 12 months, Corbus Pharmaceuticals's shares have ranged in value from as little as $0.91 up to $9.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corbus Pharmaceuticals's is 1.7882. This would suggest that Corbus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Corbus Pharmaceuticals overview

Corbus Pharmaceuticals Holdings, Inc. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co. , Ltd. for the development and commercialization of lenabasum in Japan.

Frequently asked questions

• What percentage of Corbus Pharmaceuticals is owned by insiders or institutions?

  Currently 1.163% of Corbus Pharmaceuticals shares are held by insiders and 33.838% by institutions.

• How many people work for Corbus Pharmaceuticals?

  Latest data suggests 76 work at Corbus Pharmaceuticals.

• When does the fiscal year end for Corbus Pharmaceuticals?

  Corbus Pharmaceuticals's fiscal year ends in December.

• Where is Corbus Pharmaceuticals based?

  Corbus Pharmaceuticals's address is: 500 River Ridge Drive, Norwood, MA, United States, 02062

• What is Corbus Pharmaceuticals's ISIN number?

  Corbus Pharmaceuticals's international securities identification number is: US21833P1030

• What is Corbus Pharmaceuticals's CUSIP number?

  Corbus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 21833P103